156 related articles for article (PubMed ID: 3548960)
1. Phase II trial of tiazofurin in recurrent squamous cell carcinoma of the head and neck.
Dimery IW; Neidhart JA; McCarthy K; Krakoff IH; Hong WK
Cancer Treat Rep; 1987 Apr; 71(4):425-6. PubMed ID: 3548960
[No Abstract] [Full Text] [Related]
2. Phase II evaluation of diaziquone in recurrent head and neck cancer.
Kish JA; Ensley J; Al-Sarraf M
Cancer Treat Rep; 1986 May; 70(5):671-2. PubMed ID: 3708616
[No Abstract] [Full Text] [Related]
3. Phase II trial of Baker's antifol in patients with recurrent or inoperable head and neck cancer.
Krasnow S; Green M; Perry DJ; Eisenberger MA; Johnston-Early A; Muggia F; Cohen MH
Cancer Treat Rep; 1986 Aug; 70(8):1039-40. PubMed ID: 3524834
[No Abstract] [Full Text] [Related]
4. Phase II trial of pyrazofurin in advanced head and neck cancer.
Cheng E; Currie V; Wittes RE
Cancer Treat Rep; 1979; 63(11-12):2047-8. PubMed ID: 526937
[No Abstract] [Full Text] [Related]
5. Phase II trial of thioproline in advanced epidermoid head and neck tumors.
Boccardo F; Barbieri A; Canobbio L; Guarneri D; Merlano M; Rosso R
Cancer Treat Rep; 1982 Mar; 66(3):585-6. PubMed ID: 7060048
[No Abstract] [Full Text] [Related]
6. Carboplatin, an active drug in advanced head and neck cancer.
de Andres Basauri L; Lopez Pousa A; Alba E; Sampedro F
Cancer Treat Rep; 1986 Oct; 70(10):1173-6. PubMed ID: 3530443
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of bisantrene in advanced epidermoid carcinoma of the head and neck.
Forastiere AA; Crain SM; Garbino C; Tipping SJ; Perry DJ; Kasdorf H; Van Echo DA
Cancer Treat Rep; 1984 Apr; 68(4):687-8. PubMed ID: 6713424
[No Abstract] [Full Text] [Related]
8. Phase II evaluation of mitolactol in squamous cell carcinoma of the head and neck: a Southeastern Cancer Study Group Trial.
McHale MS; Velez-Garcia E; Nelson O; Williams SD; Maddox W; Birch R
Cancer Treat Rep; 1986 Jul; 70(7):925-6. PubMed ID: 3521849
[No Abstract] [Full Text] [Related]
9. Phase II trial of razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy.
Shah MK; Engstrom PF; Catalano RB; Paul AR; Bellet RE; Creech RH
Cancer Treat Rep; 1982 Mar; 66(3):557-8. PubMed ID: 7060043
[No Abstract] [Full Text] [Related]
10. Phase II trial of aclarubicin in epidermoid carcinoma of the head and neck.
Carugati AA; Olivari AJ; Campos DM; Pradier R; Woolley PV
Cancer Treat Rep; 1986 Jun; 70(6):799-800. PubMed ID: 3524828
[No Abstract] [Full Text] [Related]
11. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
[TBL] [Abstract][Full Text] [Related]
12. [Phase II trial of mitoguazone in patients with recurrent extensive cervicofacial tumors].
Coninx P; Nasca S; Jezekova D; Roelandt H; Morel M; Legros M; Cattan A
Bull Cancer; 1985; 72(2):153-4. PubMed ID: 4005436
[No Abstract] [Full Text] [Related]
13. Phase II study of tiazofurin in colorectal cancer: a National Cancer Institute of Canada Study.
Maroun JA; Eisenhauer E; Cripps C; Maksymiuk A
Cancer Treat Rep; 1987 Dec; 71(12):1297-8. PubMed ID: 3690542
[No Abstract] [Full Text] [Related]
14. Phase II evaluation of pyrazofurin in patients with carcinoma of the lung.
Gralla RJ; Currie VE; Wittes RE; Golbey RB; Young CW
Cancer Treat Rep; 1978 Mar; 62(3):451-2. PubMed ID: 348315
[No Abstract] [Full Text] [Related]
15. Phase II trial of amsacrine in metastatic or locally recurrent squamous cell carcinoma from head and neck primaries: a Southwest Oncology Group study.
Witherspoon RP; Legha SS; Reimer RR; Talley RW; Stuckey WJ; Dixon DO; McCracken JD; Stephens RL; Oishi N
Cancer Treat Rep; 1984 Feb; 68(2):435-6. PubMed ID: 6546532
[No Abstract] [Full Text] [Related]
16. Phase II trial of 4'-epi-doxorubicin in advanced carcinoma of head and neck origin.
Magee MJ; Howard J; Bosl GJ; Wittes RE
Cancer Treat Rep; 1985 Jan; 69(1):125-6. PubMed ID: 3855384
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Elser C; Siu LL; Winquist E; Agulnik M; Pond GR; Chin SF; Francis P; Cheiken R; Elting J; McNabola A; Wilkie D; Petrenciuc O; Chen EX
J Clin Oncol; 2007 Aug; 25(24):3766-73. PubMed ID: 17704426
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
Pivot X; Raymond E; Laguerre B; Degardin M; Cals L; Armand JP; Lefebvre JL; Gedouin D; Ripoche V; Kayitalire L; Niyikiza C; Johnson R; Latz J; Schneider M
Br J Cancer; 2001 Sep; 85(5):649-55. PubMed ID: 11531245
[TBL] [Abstract][Full Text] [Related]
19. Tiazofurin: biological effects and clinical uses.
Tricot G; Jayaram HN; Weber G; Hoffman R
Int J Cell Cloning; 1990 May; 8(3):161-70. PubMed ID: 2189014
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck.
Sandler S; Bonomi P; Taylor B; Showel J; Slayton R; Lerner H
Cancer Treat Rep; 1984 Sep; 68(9):1163-5. PubMed ID: 6541095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
